The U.S. Food and Drug Administration approved GlaxoSmithKline Plc’s HIV drug Rukobia to treat adult patients who have run out of treatment options.
The death toll from COVID-19 surpassed half a million people, according to a Reuters tally, a grim milestone for the global pandemic that seems to be resurgent in some countries even as other regions are still grappling with the first wave.
Merck’s investigational pneumonia vaccine V114 hit the mark in two Phase III studies, including one involving adult HIV patients.
Shares of Epizyme stock rose after the company’s first-in-class EZH2 inhibitor Tazverik won approval from the U.S. Food and Drug Administration for the second time in 2020.
Merck’s vaunted checkpoint inhibitor Keytruda won U.S. approval for a new indication.
The U.S. Food and Drug Administration approved Viela Bio’s Uplizna (inebilizumab-cdon) for adults with neuromyelitis optica spectrum disorder who are anti-AQP4 antibody positive.
Children have milder COVID-19 symptoms than adults and the balance of evidence suggests they may also have lower susceptibility and infectivity than adults, scientists advising the British government said.
Oxford University and AstraZeneca are recruiting around 10,000 adults and children in Britain for trials of an experimental coronavirus vaccine, a day after receiving U.S. backing worth up to $1.2 billion.
The U.S. Food and Drug Administration approved Farxiga (dapagliflozin) for the treatment of heart failure in adults with reduced ejection fraction.
Merck’s vaunted checkpoint inhibitor Keytruda picked up another regulatory approval. The U.S. Food and Drug Administration approved an additional recommended dosage of 400 mg every six weeks for the anti-PD-1 therapy across all adult indications, including as a monotherapy and in combination treatments.